Publications

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

publications-magnifyglass.png

These top level issues are discussed in our White Papers, leveraging our industry expertise to help customers answer the most challenging preclinical research questions.

Oncology

Precision Profiling

Oncology drug development has an overly high attrition rate for novel agents in late-phase clinical trials, which needs to be improved to enhance the efficiency and cost-effectiveness of developing new therapies. Precision profiling using Patient-Derived Xenografts (PDX), the most predictive preclinical models available, allows the identification of molecular biomarkers and genetic signatures of response for patient stratification to improve response and reduce attrition rates. Let CrownBio’s Precision Profiling White Paper help you understand who will benefit from your treatment before you enter the clinic.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.

Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi. Nam liber tempor cum soluta nobis eleifend option congue nihil imperdiet doming id quod mazim placerat facer possim assum.

Typi non habent claritatem insitam; est usus legentis in iis qui facit eorum claritatem. Investigationes demonstraverunt lectores legere me lius quod ii legunt saepius.

Claritas est etiam processus dynamicus, qui sequitur mutationem consuetudium lectorum. Mirum est notare quam littera gothica, quam nunc putamus parum claram, anteposuerit litterarum formas humanitatis per seacula quarta decima et quinta decima.

Eodem modo typi, qui nunc nobis videntur parum clari, fiant sollemnes in futurum.